epilepsy than in women, while in women number of and perceived adverse events caused by AED had the highest impact [20] . Similar data aiming on moderators for anxiety and depression could not be identified, which illustrates the striking lack of research in this field.
In summary, the role of anxiety and depressive disorders in patients with epilepsy is complex and hard to disentangle from interactions of medical and psychosocial issues. This opens room for several questions regarding the additional impact of gender differences on depressive symptoms or anxiety in PWE that have received surprisingly little attention so far. Hence, the aims of the study were (1) to assess gender differences in prevalence of anxiety and depression in PWE, (2) to identify predictors for depression and anxiety in men and women with epilepsy, and (3) to determine whether associations between predictors and depressive symptoms or anxiety, respectively, were moderated by gender.
Methods

Study population and measurement
Adult PWE were recruited at the outpatient clinic of the Department of Neurology, Charité University Hospital Berlin, which serves as a tertiary referral center. Patients were consecutively enrolled into this study between February 2011 and March 2012. Inclusion criteria were age !18 years, definite diagnosis of epilepsy as defined by the International League against Epilepsy [21] , and the physical, mental, and language ability to complete the interview adequately. Patients under legal guardianship were excluded. All patients signed informed consent and the study was approved by the local ethics committee (EA2/133/10). Data considered in this analysis were obtained by standardized selfreport questionnaires. Adverse events of AED were assessed by patients' perception (''Have you ever/in the last 3 months experienced side effects of your antiepileptic medication?''). Additional clinical data were obtained from medical records of the epilepsy outpatient clinic. We collected demographic and clinical information including age at epilepsy onset, age at interview, sex, body mass index (BMI), epilepsy syndrome and etiology, epilepsy duration, seizure frequency (occurrence of all types of seizures in the last 3 months and generalized tonic-clonic seizures more than once/year as dichotomized variables), adverse events, and current AED treatment. To take potential psychiatric side effects possibly influencing depressive symptoms and anxiety into account, we performed a subanalysis in patients treated with AED-monotherapy since side effects can hardly be disentangled in polytherapy. AED were categorized with respect to potential for psychiatric side effects based on current literature [13] [14] [15] [16] : AED given in monotherapy with ''potential favorable psychotropic effect'' (e.g. mood-stabilizing, anxiolytic) were carbamazepine, oxcarbazepine, lamotrigine, pregabaline and valproic acid. The group of AED-monotherapies with ''potential unfavourable psychotropic effect'' (e.g. affective symptoms) comprised phenobarbital, primidone, levetiracetam and topiramate. Levels of education were categorized into three groups: Low, medium and high educational level representing up to 9 years, 10 years and 13 years of schooling, respectively. Quality of life was assessed by means of the QOLIE-31-P. In the present analysis, we focused on the QOL subscales ''seizure worry'' (e.g. ''How fearful are you of having a seizure during the next month?'') and ''medication effects'' (e.g. ''How worried are you, that medications you are taking will be bad for you if taken for a long time?''). To assess general anxiety, we used the anxiety module of the Hospital Anxiety and Depression Scale HADS-A [22] , a standardized questionnaire which has shown a high validity in evaluating symptoms of anxiety in patients with chronic diseases [23] , and also in PWE [24] . The HADS-A consists of seven questions, each question offering four possible answers, which are scored from 0 to 3 points, generating a total score from 0 to 21 points, with higher scores indicating higher levels of anxiety. To assess the severity of depressive symptoms we used the depression module of the Patient Health Questionnaire PHQ-9, a standardized nine-item scale based on DSM-IV-criteria for diagnosis of depression [25] . Items are endorsed on a 4-point Likert scale ranging from ''not at all'' to ''nearly every day''. The sum score ranges from 0 to 27 points, with higher scores indicating higher levels of depression.
Statistical analysis
Gender differences were compared using the Student's t-test for continuous, and Chi-square-tests for categorical variables, respectively. To examine relationships between depression or anxiety and sociodemographic, psychosocial and clinical variables, Pearson's r was calculated. To examine interactions between different predictors of anxiety and depression, respectively, and gender, interaction terms were computed and added to the respective main effects in the regression equation. Evaluation of assumptions led to transformation of the PHQ-9 sum score using a square root transformation to reduce skewness and improve normality. QOL medication effects and QOL seizure worries were still positively skewed after the transformation and thus dichotomized using the median of the original scale as the cut-off (Median QOL medication effects 42.0; Median QOL seizure worries 73.0).
We used sequential multiple regression analyses to evaluate the independent influence of all variables on depression and anxiety (see [26] for more details). Within these analyses, sociodemographic variables were entered in the first step, epilepsy-related variables in the second step, and medicationrelated variables in the third step. The variables were chosen relying on previous research and entered the equation according to theoretical considerations. To avoid overfitting, we drew on results of bivariate analysis and, in addition to sociodemographic variables, included only variables in respective multiple regression equation that showed a significant correlation with either depression or anxiety. All regression models were tested for multicollinearity. Goodness of fit was assessed using HosmerLemeshow test, and the strength of association was estimated using Nagelkerke R 2 . Statistical analysis was performed using SPSS Statistics 20.0 (SPSS Inc. IL, USA). All tests for statistical significance were two-sided and an alpha level of p 0.05 was considered significant.
Results
Of the 319 patients who were asked to participate in our analysis, 6 declined to take part. Eleven patients were excluded due to questionable epilepsy diagnosis (N = 6), to incomplete questionnaires or informed consent forms (N = 4) and previously unknown legal supervision (N = 1). Finally, the patient sample (N = 302) consisted of 141 men and 161 women (53%). Men on average were significantly older than women. At onset of epilepsy women were 8 years younger than men and had more often generalized epilepsy, whereas men more often had partial epilepsy and were more frequently treated with AED polytherapy. (Table 1) Regarding somatic comorbidity, arterial hypertension (N = 56), orthopedic diseases (N = 40) and thyroid dysfunction (N = 27) were most frequently named.
Women reported significantly more pronounced depressive symptoms and more QOL seizure worry, whereas levels of anxiety and QOL medication effects in women equalled those of men (detailed characteristics are displayed in Table 1 ).
Correlations between clinical variables and anxiety or depressive symptoms
In men and women, QOL seizure worry was associated with depression and anxiety. Other variables were significantly correlated to depression or anxiety specifically in either men or women. In men, the experience of adverse effects in the last 3 months was associated with depression, whereas QOL medication effects (i.e. the fear of sequelae of long term AED therapy), were associated with depression and anxiety. In women, a diagnosis of partial epilepsy and occurrence of seizures in the last 3 months showed a positive correlation with depression and anxiety, whereas generalized epilepsy was conversely correlated with these variables. In female patients, antiepileptic polytherapy and AED with potential unfavorable psychotropic effects were also associated with depressive symptoms. PWE treated with AED with potentially favorable psychotropic effects showed fewer depressive symptoms (Table 2) .
To examine the unique contribution of epilepsy-and medication-related variables in the explanation of depressive symptoms, a sequential multiple regression analysis was performed (Table 3) .
DR
2 refers to the amount of variance of depression explained by the respective variables entered in each step into the regression model. Neither in men nor in women did sociodemographics significantly explain variance in depression. In men, R 2 was significantly different from zero after entry of epilepsy-related variables in the second step (DR 2 = .10) and from medicationrelated variables in the third step (DR 2 = .13). In this multiple regression, QOL seizure worry, adverse effects in the last 3 months, and QOL medication effects remained significant predictors. In women, seizures in the last 3 months, QOL seizure worry, and AED with unfavorable psychotropic effects were independently associated with depressive symptoms. However, only epilepsy-related variables led to a significant change in R 2 (DR 2 = .17).
Results from the sequential multiple regression analyses on anxiety are shown in Table 4 . In men, only epilepsy-related variables led to a significant change in R 2 (DR 2 = .17). The size of the relationships suggests that QOL seizure worry was the most important predictor, explaining almost 17% of the variability of anxiety in men. In addition to QOL seizure worry, age and QOL medication effects were independently associated with higher levels of anxiety. However, addition of QOL medication effects did not reliably improve R 2 . In women, generalized epilepsy and QOL seizure worry were the only independent predictors in the sequential regression analysis, with epilepsy-related variables leading to a small, but significant change of R 2 (DR 2 = .11).
To assess whether the strength of associations between independent and dependent variables differed among men and women, we conducted additional regression analyses with the whole sample including interaction effects. In these multiple regression analyses, the interaction between gender and QOL medication effects reached significance with respect to both anxiety (b = .49; p = .008) and depressive symptoms (b = .58; p = .001) with stronger associations for men. In addition, the interaction between QOL seizure worries and gender with anxiety as dependent variable was also significant (b = .36; p = .043). Again, QOL seizure worries and anxiety were more closely associated in men.
Discussion
The main aim of this study was to assess possible gender differences in anxiety and depression in PWE. We have identified three key findings. First, men in our population do not exhibit lower levels in anxiety than women, as opposed to the general population. On the other hand, the expected gender difference in depression, with higher depression scores in women, is actually also seen in PWE. Second, the most important predictors for anxiety and depression are QOL medication effects (worries about AED adverse effects and perceived adverse effects) and QOL seizure worry (worries about possible seizures) and not the actual health status. Third, in men QOL medication effects and QOL seizure worry are stronger predictors for anxiety than in women.
Anxiety in men and women with epilepsy
High levels of anxiety in PWE without a gender difference is striking because in the general population men and women show a pronounced and consistent difference in anxiety, with women experiencing higher anxiety levels than men [27] . Commonly, this gender difference is even more pronounced in patients with other chronic medical conditions such as coronary heart disease [28, 29] . Table 3 Sequential regression analysis of depressive symptoms a on sociodemographic, epilepsy related, and medication related variables.
Men Women
Step Table 4 Sequential regression analysis of anxiety on sociodemographic, epilepsy related, and medication related variables.
Step Our finding of a lacking gender difference regarding anxiety is in line with previous studies [20, 30] , but so far it has not gained much attention. Yet the lack of difference in this context is such a discrepancy that it requires explanation. In our study, the reason for the unusual finding is clearly attributable to higher anxiety levels in men compared to the healthy men in the norm population. Even though women with epilepsy also report higher anxiety levels than women of the norm sample, the levels of men in our sample are so much higher that they equal those of women (HADS norm sample N = 4410 [31] ; Supplemental Fig. 1 ).
Multiple regression analysis indicates the most important predictors for anxiety in the current cohort. In men, QOL seizure worry and QOL medication effects clearly emerge as the most important predictors after controlling for epilepsy characteristics. In women, no medication-related variable is independently related to anxiety. As in men, QOL seizure worries are associated with anxiety, but in women this association is much weaker. Altogether, QOL seizure worry and QOL medication explain about 18% of variance in men, but only 11% in women. This leads to the assumption that seizure worries and the perception of medication effects may be more stressful for men than for women. Even though gender stereotypes have weakened over the last 20 years, social roles of men and women still differ [32] . Men still seem to be under more pressure to have a successful career and to be able to support a family. Therefore, a severe chronic disease like epilepsy which may be associated with a looming loss of control may still be even more stressful for men than for women (cf. [20] ). In addition, it is still socially less accepted for men to express feelings of uncertainty and anxiety, which makes it more difficult for physicians and relatives to bring up this issue and to help male patients to deal with their emotions. A third point which may contribute to higher anxiety levels in men is the fact that due to the age-dependent distribution of epilepsy syndromes on average men are 8 years older at the onset of epilepsy than their female counterparts. Therefore, at the onset men may be more advanced in their psychosocial development, but on the contrary they may also be less flexible in developing adaptive coping strategies. Thus, men may need more information on medication and on epilepsy. One clinical implication of enhanced anxiety in male PWE may be tailored AED treatment omitting substances that have the potential to induce or enhance anxiety (for review, see [33] ).
Depressive symptoms in men and women with epilepsy
Our results indicate that women with epilepsy report more depressive symptoms than men, a finding which is also present in the general population (PHQ norm sample N = 2066, [34] ; Supplemental Fig. 2 ). Similar to anxiety, QOL seizure worries were independently predictive of depression in both genders. In men, depression was also independently associated to medication effects, in particular to worries about medication effects. In both genders, the explanation of variance in depression was not due to sociodemographic factors, but almost exclusively due to epilepsyand medication-related variables. In clinical practise, it can be very difficult to define the main reason for psychiatric disorders in PWE, because many factors may have a significant impact. However, this study shows some interesting associations, and as most of the detected predictors for depression seem accessible to modification, the findings provide further support for the importance of educational interventions. In order to increase quality of life and to prevent suicide, which is still one of the main causes of death in PWE [35] , screening for depression and searching for possible causes should become part of the clinical routine. This is still not the case as almost 80% of US neurologists do not routinely screen for depressive symptoms in their epilepsy outpatients [36] . Of course, the association between depression and medication effects is likely to be bidirectional: medication effects and worries about medication effects may enhance depressive symptoms, whichvice versa -may well also reinforce the perception of adverse effects of antiepileptic drugs [37] .
Limitations
There are possible limitations to this study which should be taken into account when interpreting its results. First, the PHQ-9 is a brief screening instrument to assess severity of depressive symptoms. It does not replace the need to make a formal clinical diagnosis of depression. However, given the strong evidence for its high sensitivity and specificity, this instrument seems appropriate for investigating epidemiological questions. Another limitation refers to the norm samples for depression and anxiety that are not differentiated by age and education. This might influence the comparability. However, many studies have shown that the effect of gender in this context is usually greater than the effect of age and education. Second, the cross-sectional design does not allow for causal interpretations. Further studies are needed to clarify the direction of the influence. Third, all patients were recruited at a single center in a specialized outpatient clinic hampering generalizability of our findings. It is possible that difficult-to-treat epilepsies are overrepresented and that the study sample reflects a slightly selected, less healthy population. Fourth, some basic demographic and epilepsy variables differed between men and women well reflecting the everyday clinical setting. However, we carefully controlled for these differences, which allows for reliable interpretation of the current findings. Finally, we are well aware that data on favorable and unfavorable neuropsychiatric medication effects are not homogeneous, with new evidence still coming up. Nevertheless, we consider the potential influence of AED on neuropsychiatric symptoms a very important issue. In spite of some inconsistencies, we therefore included this aspect in patients treated with AED-monotherapy.
Conclusion
Men with epilepsy exhibit markedly higher levels of anxiety than healthy male controls eventually equalling those of female epilepsy patients. Particularly in men, anxiety and depression are significantly associated with seizure and medication worries. Further studies are needed to show whether comprehensive information about antiepileptic drugs and epilepsy itself may improve quality of life and thereby yield a positive impact on anxiety and depression. Our results suggest that such interventions should be tailored to the different needs of men and women.
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